Loading...
XSHG600222
Market cap396mUSD
Jan 09, Last price  
5.24CNY
1D
-2.96%
1Q
6.72%
Jan 2017
-37.47%
Name

Henan Taloph Pharmaceutical Stock Co Ltd

Chart & Performance

D1W1MN
XSHG:600222 chart
P/E
66.73
P/S
1.40
EPS
0.08
Div Yield, %
1.73%
Shrs. gr., 5y
-0.40%
Rev. gr., 5y
11.62%
Revenues
2.07b
+5.57%
204,039,928251,323,122364,543,024371,161,160612,737,823813,143,522913,303,032980,781,7741,089,130,6071,304,674,9151,254,230,2361,017,380,811953,306,5131,168,390,5391,194,794,3471,311,814,8181,417,097,3111,604,516,9401,960,694,3092,069,908,736
Net income
44m
16,247,71317,043,75118,036,16420,693,33123,167,89130,147,15224,271,59612,751,28520,198,64036,059,50232,034,8055,556,9984,015,5865,127,151045,711,88829,240,8625,995,375043,556,724
CFO
44m
18,251,900276,3041,593,99521,335,10418,133,18321,444,9240105,20187,445,902089,541,77949,269,48570,602,08323,169,371119,469,14643,700,58973,427,54699,655,159043,737,575
Dividend
Jul 09, 20240.018 CNY/sh

Profile

Henan Taloph Pharmaceutical Stock Co., Ltd. researches, produces, and sells Chinese and western medicines in China. It primarily offers its products in the forms of oral liquids, tablets, capsules, fluids, and other forms. The company's principal products include Huperzine A tablets, phenoxybenzamine hydrochloride tablets, pazufloxacin mesylate sodium chloride injections, and various infusion products. It serves hospitals, pharmacies, and patients. The company was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd. Henan Taloph Pharmaceutical Stock Co., Ltd. is based in Zhengzhou, China.
URL
http://www.taloph.com/
IPO date
Nov 05, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,069,909
5.57%
1,960,694
22.20%
Cost of revenue
1,819,762
1,834,985
Unusual Expense (Income)
NOPBT
250,147
125,709
NOPBT Margin
12.08%
6.41%
Operating Taxes
(1,867)
Tax Rate
NOPAT
252,014
125,709
Net income
43,557
 
Dividends
(50,169)
(5,630)
Dividend yield
1.45%
0.16%
Proceeds from repurchase of equity
(42,353)
11,412
BB yield
1.23%
-0.32%
Debt
Debt current
471,124
435,980
Long-term debt
362,371
250,419
Deferred revenue
3,259
1,714
Other long-term liabilities
1,615
9,948
Net debt
(36,854)
(115,912)
Cash flow
Cash from operating activities
43,738
CAPEX
(43,133)
Cash from investing activities
(205,120)
134,119
Cash from financing activities
26,564
FCF
114,806
519,437
Balance
Cash
349,966
386,340
Long term investments
520,383
415,971
Excess cash
766,853
704,277
Stockholders' equity
1,033,583
982,211
Invested Capital
1,605,619
1,541,815
ROIC
16.01%
7.12%
ROCE
10.43%
5.53%
EV
Common stock shares outstanding
562,748
566,688
Price
6.13
-3.77%
6.37
-29.06%
Market cap
3,449,648
-4.44%
3,609,801
-28.26%
EV
3,457,689
3,537,494
EBITDA
318,075
188,693
EV/EBITDA
10.87
18.75
Interest
917
62,983
Interest/NOPBT
0.37%
50.10%